Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

March 15, 2010 (Vol. 30, No. 6)

Oligo Therapeutics Enriching Pipelines

As Development Escalates, Delivery Strategies, Chemistries, and Modifications Also Improve

  • Market research figures compiled by Agilent Technologies reveal that in 2009, $407 million in direct financing was targeted to the development of oligonucleotide therapeutics in the U.S. This figure represents a combination of publically announced venture capital, private placement, IPO, secondary financing, and up-front collaboration payments. The total ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.